600713 南京医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)5.8218.5989.29311.23211.399
总资产报酬率 ROA (%)1.2421.9321.9242.0712.050
投入资产回报率 ROIC (%)2.1903.3413.7884.1603.721

边际利润分析
销售毛利率 (%)5.9496.2826.1836.4906.509
营业利润率 (%)1.6811.9061.8801.8601.874
息税前利润/营业总收入 (%)2.5632.8292.8232.6712.838
净利润/营业总收入 (%)1.2881.3841.3301.4261.353

收益指标分析
经营活动净收益/利润总额(%)111.235104.12596.540114.275104.192
价值变动净收益/利润总额(%)0.2880.4000.877-5.369-10.459
营业外收支净额/利润总额(%)2.418-1.994-3.003-3.125-0.816

偿债能力分析
流动比率 (X)1.4461.6271.4011.3131.339
速动比率 (X)1.1381.2591.0891.0531.081
资产负债率 (%)76.62474.61074.46478.84879.781
带息债务/全部投入资本 (%)58.88560.54955.94856.49863.038
股东权益/带息债务 (%)64.97461.10873.36471.61852.905
股东权益/负债合计 (%)26.73429.87930.41924.04222.304
利息保障倍数 (X)3.0492.9462.8293.0822.899

营运能力分析
应收账款周转天数 (天)93.57679.61987.57190.10679.332
存货周转天数 (天)44.99443.22341.47839.49836.623